ABSI
NASDAQ · Biotechnology
Absci Corp
$8.93
+0.63 (+7.59%)
Financial Highlights (FY 2026)
Revenue
3.58M
Net Income
-147,099,603
Gross Margin
—
Profit Margin
-4,113.7%
Rev Growth
-21.3%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 58.4% | 58.4% |
| Operating Margin | -4,297.0% | -3,867.3% | -17.8% | -17.1% |
| Profit Margin | -4,113.7% | -3,908.0% | -15.3% | -17.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.58M | 4.55M | 58.57M | 57.07M |
| Gross Profit | — | — | 34.21M | 33.33M |
| Operating Income | -153,876,057 | -176,037,182 | -10,406,862 | -9,769,969 |
| Net Income | -147,099,603 | -168,284,787 | -8,944,093 | -9,875,873 |
| Gross Margin | — | — | 58.4% | 58.4% |
| Operating Margin | -4,297.0% | -3,867.3% | -17.8% | -17.1% |
| Profit Margin | -4,113.7% | -3,908.0% | -15.3% | -17.3% |
| Rev Growth | -21.3% | -21.3% | +10.3% | +2.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.46M | 3.46M | 100.48M | 118.62M |
| Total Equity | 752.91M | 752.91M | 298.85M | 311.81M |
| D/E Ratio | 0.00 | 0.00 | 0.34 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -138,662,468 | -167,445,461 | -15,160,350 | -13,058,914 |
| Free Cash Flow | — | — | -10,726,027 | -11,756,277 |